JKS is caught in an unusual split this week — the stock fell nearly 6% over five sessions, yet short sellers are actively reducing exposure while options traders pile into calls at an extreme not seen all year.
The options signal is the sharpest data point on the board right now. The put/call ratio dropped to 0.45 on Tuesday — the lowest reading of the past 52 weeks, against a 52-week high of 1.72. More striking, that reading sits nearly four standard deviations below the 20-day average of 0.52. In practical terms, call buyers are dominating options flow by a margin that has no recent precedent for this stock. That reads as aggressive bullish positioning, not cautious hedging — and it sits in direct tension with a share price that just lost 4% on Tuesday alone.
Short interest tells a quieter but directionally consistent story. Bears have been pulling back all month. Short interest fell 6.7% in a single session on Tuesday to 5.5% of the free float — and is down roughly 19% from a month ago, when shorts held a meaningfully larger position. The lending market is relaxed: borrow costs ticked up 21% on the week to 0.66%, but that remains a very low absolute level. Availability is comfortable at 212%, meaning roughly two shares are available to borrow for every one already lent out — well clear of the 52-week tightest reading of 104%. The setup offers no mechanical squeeze pressure. Shorts are leaving by choice, not necessity.
Where the Street stands is harder to read cleanly. The most recent analyst data is from late July — borderline stale — with the consensus price target around $25.44 against a current price of $15.50, implying roughly 64% upside in aggregate. But that headline figure masks a divided field. Goldman Sachs has held a Sell rating through multiple target revisions, most recently lifting to $20 in November 2025. UBS sits at Neutral with a $24 target raised in May. Daiwa Capital made the boldest move, upgrading all the way from Sell to Buy with a $28.50 target back in March. The overall picture is a Street that has become incrementally less bearish but remains far from consensus bullish. Valuation multiples offer little comfort on earnings — the P/E is deeply negative and EV/EBITDA has drifted lower over 30 days — though the price-to-book of 0.29x reflects an extremely cheap asset base. Factor scores are poor across earnings momentum and EPS surprise, both ranking in the bottom 5% of the universe.
The institutional picture adds some texture. BlackRock added 536,000 shares as of end-July, Storebrand added 530,000, and UBS Asset Management added 479,000 — each building positions meaningfully in Q2. On the insider side, the net 90-day picture is complicated by a large award cycle in May alongside an $8.2 million open-market sale by founder Xianhua Li at $6.38 per share. That sale price is well below the current $15.50, suggesting the transaction predates the recent recovery, but the scale — 1.28 million shares — is worth noting. Li's institutional holding has since been trimmed further, dropping 127,000 shares by mid-May.
JKS reports earnings today (August 26), making this week's positioning data the final pre-print read. The one prior earnings reaction in the dataset showed a modest 1.8% next-day gain after the August 21 event. With shorts at a multi-month low, calls at a 52-week extreme, and a stock down 38% year-to-date against a mean analyst target implying roughly 64% upside, the next session will reveal whether the aggressive call positioning and short-seller retreat reflected genuine information — or whether the stock's persistent downtrend reasserts itself.
See the live data behind this article on ORTEX.
Open JKS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
